Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALNANASDAQ:BBINASDAQ:BCDANASDAQ:CYTRNASDAQ:LIFE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALNAAllena Pharmaceuticals$0.07$0.06▼$1.17$37K1.1315.69 million shs96,558 shsBBIBrickell Biotech$0.86$2.21▼$37.35$6.75M0.02206,730 shs31,300 shsBCDABioCardia$2.11+1.4%$2.29$1.63▼$4.66$10.93M0.81274,905 shs3.04 million shsCYTRLadRx$0.09$0.05▼$0.86$4.14MN/A99,706 shs4,000 shsLIFEaTyr Pharma$1.76$1.08▼$2.45$131.12M1.19514,103 shs269,400 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALNAAllena Pharmaceuticals0.00%0.00%0.00%0.00%0.00%BBIBrickell Biotech0.00%0.00%0.00%0.00%0.00%BCDABioCardia+1.44%-5.38%-3.21%+4.98%-29.43%CYTRLadRx0.00%0.00%0.00%0.00%0.00%LIFEaTyr Pharma0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALNAAllena PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ABBIBrickell BiotechN/AN/AN/AN/AN/AN/AN/AN/ABCDABioCardia4.0078 of 5 stars3.85.00.00.03.82.50.6CYTRLadRxN/AN/AN/AN/AN/AN/AN/AN/ALIFEaTyr PharmaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALNAAllena Pharmaceuticals 0.00N/AN/AN/ABBIBrickell Biotech 0.00N/AN/AN/ABCDABioCardia 3.50Strong Buy$25.001,084.83% UpsideCYTRLadRx 0.00N/AN/AN/ALIFEaTyr Pharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALNAAllena PharmaceuticalsN/AN/AN/AN/A$0.23 per shareN/ABBIBrickell Biotech$4.64M0.00N/AN/A$9.75 per share0.00BCDABioCardia$60K182.16N/AN/A$0.18 per share11.72CYTRLadRxN/AN/AN/AN/AN/AN/ALIFEaTyr Pharma$350K0.00N/AN/A$1.54 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALNAAllena Pharmaceuticals-$48.66MN/A0.00N/AN/AN/A-287.46%-146.58%N/ABBIBrickell Biotech-$39.47M-$13.52N/AN/AN/A-643.48%-156.10%-128.23%N/ABCDABioCardia-$7.95M-$2.33N/AN/AN/AN/A-30,792.60%-223.06%8/12/2025 (Estimated)CYTRLadRxN/AN/A0.00N/AN/AN/AN/AN/AN/ALIFEaTyr Pharma-$50.39M-$0.90N/AN/AN/AN/A-56.92%-43.87%N/ALatest ALNA, LIFE, BBI, CYTR, and BCDA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025BCDABioCardia-$0.39-$0.59-$0.20-$0.59N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALNAAllena PharmaceuticalsN/AN/AN/AN/AN/ABBIBrickell BiotechN/AN/AN/AN/AN/ABCDABioCardiaN/AN/AN/AN/AN/ACYTRLadRxN/AN/AN/AN/AN/ALIFEaTyr PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALNAAllena PharmaceuticalsN/A1.581.58BBIBrickell BiotechN/A6.366.36BCDABioCardiaN/A0.360.36CYTRLadRxN/AN/AN/ALIFEaTyr Pharma0.026.076.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALNAAllena Pharmaceuticals7.33%BBIBrickell BiotechN/ABCDABioCardia20.57%CYTRLadRxN/ALIFEaTyr Pharma61.72%Insider OwnershipCompanyInsider OwnershipALNAAllena Pharmaceuticals3.70%BBIBrickell Biotech4.53%BCDABioCardia20.00%CYTRLadRxN/ALIFEaTyr Pharma3.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALNAAllena Pharmaceuticals35122.08 million117.57 millionNot OptionableBBIBrickell Biotech162.87 million2.74 millionNot OptionableBCDABioCardia405.18 million4.14 millionOptionableCYTRLadRxN/A45.04 millionN/ANot OptionableLIFEaTyr Pharma5669.01 million66.46 millionOptionableALNA, LIFE, BBI, CYTR, and BCDA HeadlinesRecent News About These CompaniesPampa Metals Upsizes LIFE Offering to $6mJuly 4 at 10:02 AM | thenewswire.comTCassiar Gold Announces Brokered LIFE Offering for Gross Proceeds of up to C$5 MillionJune 25, 2025 | newsfilecorp.comNSilver North Announces Charity Flow Through LIFE Private Placement for Gross Proceeds of up to C$2.1 MillionJune 23, 2025 | thenewswire.comTTier One Silver Updates LIFE Financing and Receives Bridge LoanJune 23, 2025 | newsfilecorp.comNDefiance Silver Corp. Announces Closing of Brokered LIFE Offering and Concurrent Non-Brokered Offering for Total Gross Proceeds of C$16.5 MillionJune 20, 2025 | newsfilecorp.comNCoTec Holdings Corp. Announces Initial Closing of Life Offering and Concurrent Private PlacementJune 18, 2025 | accessnewswire.comAPampa Metals Announces $5 million LIFE OfferingJune 13, 2025 | thenewswire.comTaTyr: Promising Data, But Cash May Be An IssueJune 10, 2025 | seekingalpha.comArgyle Closes C$1 Million LIFE OfferingJune 9, 2025 | newsfilecorp.comNDefiance Silver Corp. Announces Upsize of the Brokered LIFE Offering and Non-Brokered Private Placement for Aggregate Gross Proceeds of up to C$14.5 MillionJune 5, 2025 | newsfilecorp.comNDefiance Silver Corp. Announces Brokered LIFE Offering for Gross Proceeds of up to C$8 MillionJune 4, 2025 | newsfilecorp.comNArgyle Announces up to C$1 Million LIFE OfferingMay 26, 2025 | newsfilecorp.comNVortex Energy Corp. Closes Listed Issuer Financing Exemption (LIFE) Private PlacementMay 22, 2025 | globenewswire.comaTyr Pharma, Inc. (ATYR): Analysts See 485% Upside PotentialMay 21, 2025 | insidermonkey.comVortex Energy Corp. Announces Listed Issuer Financing Exemption (LIFE) Private PlacementApril 24, 2025 | globenewswire.comLithiumBank Announces Closing of Final Tranche of LIFE Private PlacementApril 8, 2025 | newsfilecorp.comNIs aTyr Pharma (ATYR) The Hot Biotech Stock Under $5?March 27, 2025 | insidermonkey.comaTyr Pharma (ATYR) Receives a Buy from Wells FargoMarch 18, 2025 | markets.businessinsider.comaTyr Pharma director buys $15K in common stockMarch 18, 2025 | markets.businessinsider.comaTyr Pharma’s Earnings Call Highlights Progress and ChallengesMarch 14, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseGE Aerospace Turns Engines Into Long-Term ProfitsBy Jeffrey Neal Johnson | June 21, 2025View GE Aerospace Turns Engines Into Long-Term ProfitsHSAs for Gym Memberships? These 3 Fitness Stocks Could SoarBy Chris Markoch | June 24, 2025View HSAs for Gym Memberships? These 3 Fitness Stocks Could SoarALNA, LIFE, BBI, CYTR, and BCDA Company DescriptionsAllena Pharmaceuticals NASDAQ:ALNAAllena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.Brickell Biotech NASDAQ:BBIBrickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.BioCardia NASDAQ:BCDA$2.11 +0.03 (+1.44%) Closing price 07/3/2025 03:57 PM EasternExtended Trading$2.09 -0.02 (-0.95%) As of 07/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.LadRx NASDAQ:CYTRLadRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor. The company was founded in 1985 and is headquartered in Los Angeles, CA.aTyr Pharma NASDAQ:LIFEaTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
